Total Number of Pages in This Submission

0286336.00153US1/NOR-014CP4

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number**

3

10/749122-Conf. #3280 Filing Date **TRANSMITTAL** December 30, 2003 First Named Inventor **FORM** Richard L. BOYD Art Unit 1645 (to be used for all correspondence after initial filing) **Examiner Name** Not Yet Assigned Attorney Docket Number

ENCLOSURES (Check all that apply) After Allowance Communication Fee Transmittal Form Drawing(s) to TC Appeal Communication to Board of Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to TC Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please **Extension of Time Request** Terminal Disclaimer Identify below): Return Receipt Postcard **Express Abandonment Request** Request for Refund Supplemental Information CD, Number of CD(s) Disclosure Statement Certified Copy of Priority Landscape Table on CD Document(s) Reply to Missing Parts/ Remarks Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name WILMER CUTLER PICKERING HALE AND DORR LLP Signature deed Clark Printed name Ann-Louise Kerner, Ph.D. Date Reg. No. June 22, 2006 33,523

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: June 22, 2006

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Rated: June 22, 2006 Signature: Lin Gha (Stephanie R. Douglas)

Docket No.: 0286336.00153US1/NOR-014CP4 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Richard L. BOYD

Confirmation No.:

3280

Application No.:

10/749122

Art Unit:

1645

Filed:

December 30, 2003

Examiner:

Not Yet Assigned

Title:

DISEASE PREVENTION BY REACTIVATION OF THE THYMUS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

This Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. No fee is required.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Respectfully submitted,

Dated: June 22, 2006

Ann-Louise Kerner, Ph.D. Registration No.: 33,523 Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street Boston, Massachusetts 02109 (617) 526-6000 (telephone) (617) 526-5000 (facsimile) JUN 2 6 2006

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/749122-Conf. #3280
- 11	NFORMATIO	ON DI	SCLOSURE	Filing Date	December 30, 2003
S	STATEMENT BY APPLICANT			First Named Inventor	Richard L. BOYD
				Art Unit	1645
	(Use as many	y sheets as	necessary)	Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	0286336.00153US1/NOR-014CP4

U.S. PATENT DOCUMENTS					
Examiner	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Initials*		Number-Kind Code ² (if known)			
	AA*	US-4,049,805	09-20-1977	Strade	
	AB*	US-5,759,551	06-02-1998	Ladd et al.	

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY			T ⁶	
	ВА	EP-0882736A1	12-09-1998	LABORATORIE THERAMEX,			
				S.A.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	CA	Gojo et al., Gene Therapy and Transplantation, (2000), Vol. 69, pp. 1-9.				
	СВ	Ross et al., "Gene Therapy in the United States: A Five-Year Status Report," Human Gene Therapy, 1996, pp. 1781-1790, Vol. 7.				
	CC	Belhadj et al., "Hepatosplenic gamma-delta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: Report of a Series of 21 Patients," Blood, 2003, pp. 4261-4269, Vol. 102.				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
	54.0
Signature	Considered

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.